Quantcast

Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr Instagram
POZ Personals
Sign In / Join
Username:
Password:
Welcome, Guest. Please login or register.
December 18, 2014, 01:25:03 PM

Login with username, password and session length


Members
Stats
  • Total Posts: 649758
  • Total Topics: 49592
  • Online Today: 284
  • Online Ever: 585
  • (January 07, 2014, 02:31:47 PM)
Users Online

Welcome


Welcome to the POZ/AIDSmeds Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ/AIDSmeds community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: vaccine using b12 antibody Fc receptors Scripps Research  (Read 1606 times)

0 Members and 1 Guest are viewing this topic.

Offline bimazek

  • Member
  • Posts: 781
vaccine using b12 antibody Fc receptors Scripps Research
« on: September 23, 2007, 07:36:20 PM »
action of the b12 antibody-one of the rare antibodies that protects against the HIV virus.
Sep 2007
http://www.medicalnewstoday.com/articles/81850.php

"Hopefully, we can work backwards towards a vaccine, using b12 and the very few other really great, broadly neutralizing antibodies against HIV that have been found," says Scripps Research Senior Research

protection was dependent upon the ability of antibodies to interact with immune cell Fc receptors.

Fc receptors are found on the surface of immune cells, such as natural killer cells. The Fc receptor binds to the Fc region of an antibody after an antibody binds to a pathogen, targeting the pathogen for attack by the immune system. Although Fc receptor function was known to be important for the function of antibodies against other diseases, a role in protecting against HIV had never before been demonstrated.

complement cascade, a major component of the immune system responsible for destroying invading pathogens.

The results provide the first evidence that the Fc receptor, but not the complement cascade, is important to the function of the b12 antibody in preventing HIV infection.

Offline J220

  • Member
  • Posts: 587
Re: vaccine using b12 antibody Fc receptors Scripps Research
« Reply #1 on: September 23, 2007, 09:45:19 PM »
Here's the actual article from Scripps, http://www.scripps.edu/newsandviews/e_20070917/burton.html. This is a very exciting discovery, and it may yield a viable vaccine. If this B12/ KA antibody can be elicited with a vaccine it could conceivably work as a preventive vaccine and either an outright cure or long term therapeutic vaccine. In essence, this b12/KA antibody has the ability to attach BOTH to virus particles and to healthy immune cells. This causes the virus particles and the cells to find each other, resulting in the destruction of the virus. Could this be the key??? We'll see!!

Researchers Shed New Light on How Antibodies Fight HIV

By Matthew Busse and Mika Ono Benedyk

Leading an international team of scientists, immunologists at The Scripps Research Institute have uncovered the first evidence that an HIV antibody is most effective when it binds not only to the virus, but also to host immune cells. The findings suggest that antibody efficiency depends on both directly neutralizing the virus and activating the host immune response.

By furthering scientists' understanding of the molecular mechanisms that separate the minority of successful HIV antibodies from the majority of ineffective antibodies, the work may have implications for future attempts to design an HIV vaccine.

The study was published on September 6, 2007, in the journal Nature.

"This study is part of the effort to understand how protection against HIV occurs," says Dennis Burton, a professor at The Scripps Research Institute. "If we really understand this, then we can design tailor-made vaccines in a way that has never been done before."

Although vaccines have long been used with great success to prevent diseases, scientists are still learning about the exact mechanisms of how vaccines work and how the antibodies that vaccines prompt the body to create can neutralize a pathogen. The spread of HIV, which is resistant to most antibodies the body produces against it, has made fully understanding this method of action more urgent.

With this in mind, Burton and colleagues sought to tease apart the action of the b12 antibody—one of the rare antibodies that protects against the HIV virus. The antibody, first identified by Burton, Scripps Research Professor Carlos Barbas III, and colleagues in 1992, originally came from the bone marrow of a 31-year-old male who had been HIV positive without symptoms for six years.

In the current study, researchers created mutated versions of b12 to see what effect various changes would have on the antibody's effectiveness.

"Hopefully, we can work backwards towards a vaccine, using b12 and the very few other really great, broadly neutralizing antibodies against HIV that have been found," says Scripps Research Senior Research Assistant Ann Hessell, who was first author of the Nature paper jointly with Lars Hangartner, a Scripps Research postdoctoral fellow.

Results from the new study suggest the importance of antibody activity against both infected cells and free virus for effective protection. As well as simply binding to HIV, protection was dependent upon the ability of antibodies to interact with immune cell Fc receptors.

Fc receptors are found on the surface of immune cells, such as natural killer cells. The Fc receptor binds to the Fc region of an antibody after an antibody binds to a pathogen, targeting the pathogen for attack by the immune system. Although Fc receptor function was known to be important for the function of antibodies against other diseases, a role in protecting against HIV had never before been demonstrated.

Burton's team examined the ability of two antibodies mutated from b12, dubbed KA and LALA, to prevent infection using the SHIV/macaque model, in which macaques are challenged with a hybrid human-simian virus that infects the model but is recognized by human antibodies. The KA antibody contained a mutation that prevented it from interacting with the complement cascade, a major component of the immune system responsible for destroying invading pathogens. The LALA antibody contained a mutation that rendered it unable to interact with either the complement pathway or the Fc receptor.

In both mutants, the site where the antibody binds to free-floating virus was unaltered, allowing the researchers specifically to investigate the importance of the complement cascade and Fc receptor system for preventing infection.

"We saw that the KA antibody, which could still bind to the Fc receptors on the immune cells but not to the complement cascade, protected the animals from becoming infected just as the wild type b12 antibody," says Hessell. "In contrast, the LALA group became infected much like the controls."

The results provide the first evidence that the Fc receptor, but not the complement cascade, is important to the function of the b12 antibody in preventing HIV infection.

Additional in vitro experiments revealed that the wild type and KA antibodies, but not the LALA antibody, blocked infection more efficiently in the presence of other effector cells of the immune system.

 "Our results are fully consistent with the antibody doing two jobs," says Burton, "job one, stick to the virus; job two, recruit immune cells to come and kill infected cells."

In addition to Burton, Hessell, and Hangartner, authors of the study, "Fc Receptor But Not Complement Binding Is Important in Antibody Protection Against HIV," are Meredith Hunter and Preston A. Marx of Tulane University; Carin E.G. Havenith, Frank J. Beurskens, Joost M. Bakker, and Paul W.H.I. Parren of Genmab (Utrecht, The Netherlands); Gary Landucci and Donald N. Forthal of University of California, Irvine, School of Medicine; and Caroline Lanigan of The Scripps Research Institute. For more information, see Nature at http://www.nature.com/nature/journal/v449/n7158/abs/nature06106.html. For a commentary on the paper, see http://www.nature.com/nature/journal/v449/n7158/full/449029a.html.

Support for this work was provided by grants from the National Institutes of Health and the Neutralizing Antibody Consortium of the International AIDS Vaccine Initiative, and by a fellowship from the Swiss National Foundation.

 

Send comments to: mbenedyk@scripps.edu


"Hope is my philosophy
Just needs days in which to be
Love of Life means hope for me
Born on a New Day" - John David

 


Terms of Membership for these forums
 

© 2014 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.